Authors: – Laxmi Praveen (Senior Research Associate, Clinpharm )
In brief: a systematic literature review (SLR) transforms fragmented clinical evidence — scattered across hundreds of publications with inconsistent reporting formats — into harmonized, traceable, decision-ready datasets by combining structured search strategies, PRISMA-compliant screening, standardized data extraction, and outcome measure harmonization, followed by rigorous quality control to ensure every extracted data point remains linked to its original source.
Introduction
The volume of scientific and clinical literature continues to grow at an unprecedented pace, with thousands of journal articles, conference abstracts, and clinical study reports published every year. While this expanding evidence base offers valuable insights for drug development and clinical research, the information is often dispersed across multiple sources, reported using different methodologies, and described with inconsistent terminology.
For researchers, clinical teams, and decision-makers, the challenge is no longer locating evidence—it is efficiently identifying relevant studies, evaluating their quality, and integrating heterogeneous data into a consistent, reliable evidence base. Without a structured methodology, comparing findings across studies becomes time-consuming and may introduce inconsistencies or bias.
Systematic Literature Review (SLR) provides a transparent and reproducible framework for identifying, evaluating, and synthesizing published evidence. By following predefined protocols and internationally accepted reporting standards, SLR enables organizations to build a trusted evidence foundation that supports informed clinical, regulatory, and strategic decisions.
The challenge of fragmented clinical evidence extends beyond literature reviews to the broader clinical data ecosystem. Excelra’s blog on Enhancing Drug Development Decisions with Analysis-Ready Clinical Datasets explores how structured, analysis-ready clinical datasets complement literature-derived evidence and support better decision-making throughout drug development.
Building the evidence foundation
However, identifying publications is only the beginning. Through systematic screening, we evaluate studies against predefined inclusion and exclusion criteria to ensure that only scientifically relevant evidence is carried forward. This step reduces noise, minimizes bias, and creates a transparent pathway from the research question to the final dataset.
Fig. 1. PRISMA diagram of identified, screened, appraised, and included studies.
In brief: a systematic literature review (SLR) transforms fragmented clinical evidence — scattered across hundreds of publications with inconsistent reporting formats — into harmonized, traceable, decision-ready datasets by combining structured search strategies, PRISMA-compliant screening, standardized data extraction, and outcome measure harmonization, followed by rigorous quality control to ensure every extracted data point remains linked to its original source.
Introduction
The scientific literature landscape is expanding rapidly, with thousands of clinical studies, conference abstracts, and research publications added to major databases every year. While this wealth of information has the potential to accelerate research and improve patient outcomes, valuable evidence often remains fragmented across multiple sources, study designs, and reporting formats.
In our work, we frequently encounter this challenge. Researchers and decision-makers need reliable answers to complex scientific questions, yet the evidence required to answer them is often scattered across hundreds of publications. Systematic Literature Review (SLR) provides a structured framework for transforming this fragmented evidence into harmonized, traceable, and decision-ready datasets that can support evidence-based decision-making.
The challenge of fragmented clinical evidence is not limited to systematic reviews — it extends to the entire ecosystem of clinical data management in drug development. Excelra’s blog on Enhancing Drug Development Decisions with Analysis-Ready Clinical Datasets examines how the same fragmentation problem manifests in clinical trial data pipelines — and how structured, analysis-ready dataset construction addresses it at the study level, complementing the literature-level approach that SLR provides.
Building the evidence foundation
However, identifying publications is only the beginning. Through systematic screening, we evaluate studies against predefined inclusion and exclusion criteria to ensure that only scientifically relevant evidence is carried forward. This step reduces noise, minimizes bias, and creates a transparent pathway from the research question to the final dataset.
Fig. 1. PRISMA diagram of identified, screened, appraised, and included studies.
The PRISMA framework — Preferred Reporting Items for Systematic Reviews and Meta-Analyses — is the international reporting standard that governs how systematic reviews document their search and screening process. A well-executed PRISMA flow ensures that the evidence base is not only complete but transparent and reproducible. For organizations seeking to understand how structured evidence generation connects to model-based meta-analysis, Excelra’s dedicated blog on Data Curation for MBMA — an Integral Part of MID3 explains how SLR outputs feed directly into MBMA models and why the quality of that upstream evidence determines the reliability of downstream quantitative analyses.
Transforming publications into structured data
Scientific publications contain valuable information, but the data is often unstructured and reported inconsistently across studies. To address this, we develop a structured extraction framework that defines the variables, data domains, and relationships required to answer the research question.
Data extraction is followed by harmonization, one of the most critical steps in the transformation process. Different studies may report the same concept using different terminology, scales, or measurement approaches. For example, average pain intensity may be reported using NPRS, NRS, BPI, VAS, BS-11, or 11-point Likert scales. Although these instruments measure a similar outcome, they differ in format and interpretation. Harmonization standardizes these measurements into a framework, enabling meaningful comparisons across studies and supporting robust evidence synthesis.
Traceability and contextual interpretation are also equally important. Every extracted data point remains linked to its original source publication, allowing us to verify findings, understand the context in which the data was reported, and maintain confidence in the resulting dataset. Context is particularly important when similar variables can represent different concepts. For example, the Brief Pain Inventory (BPI) may report both pain severity and pain interference scores. While pain severity measures the intensity of pain experienced by a patient, pain interference evaluates the impact of pain on daily functioning and quality of life. Selecting the wrong measure without understanding the study context can lead to inaccurate analyses and misleading conclusions. Traceability ensures that extracted data can always be reviewed against the source evidence, supporting scientifically defensible decisions.
Combined with predefined protocols, standardized extraction templates, and rigorous quality control procedures, these practices create a reproducible framework for evidence generation and enable the transformation of fragmented evidence into trusted clinical insights.
The traceability principle described here — every extracted data point linked to its original source — is the same principle that underlies FAIR data governance in the broader clinical data ecosystem. Excelra’s blog on FAIRification: A Path to Scientific Data Connectivity examines how Findable, Accessible, Interoperable, and Reusable data standards extend the traceability and reproducibility requirements of systematic reviews into the wider landscape of pharmaceutical data management.
For organizations that need to integrate text mining and automated data curation with systematic evidence extraction, Excelra’s blog on Integrated Text Mining and Data Curation Approaches for Biomedical Knowledgebase Development explores how NLP-driven extraction and expert curation can be combined to build scalable, high-quality biomedical evidence repositories — addressing the efficiency and reliability challenges raised by the growth of scientific literature.
From data to decisions
The true value of an SLR lies not in the dataset itself, but in the decisions it enables. Structured evidence datasets help researchers identify evidence gaps, evaluate treatment effectiveness, and support comparative analyses across therapies and patient populations.
As the volume of scientific literature continues to grow, NLP and Generative AI are increasingly being used to accelerate evidence extraction. While these technologies can improve efficiency, their probabilistic nature highlights the continued importance of traceable, auditable, and reproducible evidence-generation processes.
The intersection of NLP and clinical evidence extraction is explored in practical depth in Excelra’s whitepaper on Automating Pharmacokinetic Metadata Extraction in Drug-Drug Interaction (DDI) Studies Using NLP Technologies — demonstrating how NLP can accelerate the extraction of structured pharmacokinetic data from unstructured literature while maintaining the traceability and auditability requirements that regulatory and scientific audiences demand.
The competitive intelligence dimension of evidence synthesis — identifying where your therapy stands relative to the landscape of published clinical data — is addressed in Excelra’s case study on Data-Driven Competitive Landscape Analysis to Facilitate Go/No-Go Decision in Clinical Development — showing how structured SLR outputs directly informed a strategic clinical development decision.
Conclusion
In an era of information abundance, the challenge is no longer finding evidence — it is transforming fragmented evidence into trusted clinical insights. By combining systematic evidence identification, rigorous screening, harmonization, and reproducible workflows, we can move from data to decisions with greater confidence and clarity.
Systematic literature review, as described in this article, is a structured evidence synthesis process comprising four linked stages: comprehensive database search against a defined research question, PRISMA-compliant screening against predefined inclusion/exclusion criteria, structured data extraction with harmonization of heterogeneous outcome measures, and traceability-preserving quality control — producing a reproducible, auditable dataset that connects every clinical insight to its original source evidence. As this article concludes: in an era of information abundance, the challenge is no longer finding evidence — it is transforming fragmented evidence into trusted clinical insights.
Excelra’s Clinical Data Services team supports organizations across the full evidence-generation workflow — from systematic literature review and data extraction through harmonization, quality control, and analysis-ready dataset delivery. To explore how Excelra can support your evidence synthesis and clinical decision-making programmes, visit our Clinical Data Services page.
References
Technology integration in complex healthcare environments: A systematic literature review.
https://www.sciencedirect.com/science/article/abs/pii/S0003687020302994
What is a systematic literature review and why is it used in drug development?
A systematic literature review (SLR) is a structured, reproducible process for identifying, screening, and synthesizing all available evidence on a specific scientific question from published studies. In drug development, SLRs are used because the evidence needed to answer a clinical, regulatory, or strategic question is rarely contained in a single publication — it is typically scattered across dozens or hundreds of studies conducted in different populations, with different designs, and reporting outcomes in different formats. SLR provides a transparent, auditable methodology for consolidating this fragmented evidence: defining a precise research question, executing a comprehensive database search, screening studies against predefined inclusion and exclusion criteria, extracting data into a structured framework, and harmonizing heterogeneous outcome measures. The result is a decision-ready dataset that connects every clinical insight to its original source, supporting scientifically defensible conclusions for regulatory submissions, health technology assessments, clinical guidelines, and drug development go/no-go decisions.
What is data harmonization in a systematic literature review?
Data harmonization in a systematic literature review is the process of standardizing clinical outcome measures that different studies have reported using different instruments, scales, or terminologies into a common framework that allows meaningful comparison and synthesis. The same clinical concept — such as average pain intensity — may be measured and reported using multiple validated instruments across different studies: the Numerical Pain Rating Scale (NRS or NPRS), the Brief Pain Inventory (BPI), the Visual Analogue Scale (VAS), the Behavioral Scale 11 (BS-11), or an 11-point Likert scale. Although each instrument measures pain, they differ in format, scoring, and interpretive context. Harmonization maps these heterogeneous measurements onto a consistent framework so that they can be combined in meta-analyses or compared across studies without introducing the measurement error that would arise from treating them as interchangeable. Effective harmonization requires both methodological expertise and contextual understanding of what each instrument measures — distinguishing, for example, between pain severity and pain interference scores within the same instrument.
What is the PRISMA framework and why does it matter for systematic reviews?
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is the internationally recognised reporting standard that governs how systematic reviews document the process of identifying, screening, and selecting studies for inclusion. It specifies the key information that must be reported at each stage of the review — total records identified through database searching, records removed as duplicates, records screened, records excluded with reasons, and records ultimately included. The PRISMA flow diagram is typically presented as a visual flowchart showing exactly how many publications moved through each stage of the review process. PRISMA matters for systematic reviews in drug development because it ensures that the evidence base is transparent, reproducible, and auditable — requirements that regulatory bodies, health technology assessment agencies, and journal editors all apply to systematic reviews used in submissions, reimbursement dossiers, and clinical guidelines. Without PRISMA compliance, a systematic review’s methodology cannot be evaluated or replicated by other researchers.
How is NLP being used to accelerate systematic literature review in pharma?
Natural language processing (NLP) and generative AI are being applied to several stages of the systematic literature review process to reduce the time and manual effort required while maintaining scientific quality. In title and abstract screening, NLP classifiers trained on labelled examples can prioritise or pre-filter large sets of records, reducing the volume of manual screening required. In data extraction, NLP tools can identify and extract structured information — such as patient populations, dosing regimens, outcome measures, and study design characteristics — from unstructured publication text. Generative AI can summarise findings across large corpora or draft extraction forms from full-text publications. However, the probabilistic nature of NLP and generative AI means that their outputs require expert human review and cannot replace the traceability and auditability requirements that define a defensible systematic review. NLP accelerates the process; it does not change the requirement that every extracted data point must be verifiable against its source.
What is traceability in clinical evidence data extraction and why does it matter?
Traceability in clinical evidence data extraction means that every extracted data point remains explicitly linked to the specific publication, page, table, and figure from which it was taken — so that any finding in the final dataset can be independently verified against the original source. This matters for several reasons. First, accuracy: traceability allows errors introduced during extraction to be identified and corrected at the source rather than propagating through downstream analyses. Second, context: the same variable can represent different concepts depending on its reporting context — the Brief Pain Inventory’s pain severity and pain interference scores are an example — and traceability enables reviewers to return to the source to verify which concept was actually measured. Third, defensibility: regulatory agencies, HTA bodies, and peer reviewers expect that systematic review datasets can be audited back to their sources. Without traceability, a dataset cannot be considered scientifically defensible regardless of how rigorous the extraction process appears to have been.
What is the difference between a systematic literature review and a model-based meta-analysis?
A systematic literature review (SLR) is the evidence-gathering process: identifying, screening, and extracting structured data from published studies on a defined research question. A model-based meta-analysis (MBMA) is the quantitative analysis that uses SLR outputs as inputs: fitting a pharmacokinetic or pharmacodynamic model to the harmonized, extracted data to characterize dose-response relationships, estimate treatment effects, or optimize trial design. The relationship between them is sequential and dependent. An MBMA is only as reliable as the SLR data it is built on — if the upstream evidence extraction is incomplete, inconsistently harmonized, or lacks traceability, the MBMA model will produce unreliable outputs regardless of its sophistication. In practice, MBMA programs typically begin with a purpose-built SLR designed specifically to extract the data domains the model will require — meaning that the extraction framework is developed with the modelling question in mind rather than as a general evidence survey. This makes SLR and MBMA complementary tools within the MID3 (Model-Informed Drug Discovery and Development) framework.
Ready to Transform Fragmented Evidence into Decision-Ready Insights?
Excelra's Clinical Data Services team delivers systematic literature reviews, structured data extraction, outcome measure harmonization, and analysis-ready datasets that support evidence-based decision-making across drug development, HEOR, and medical affairs. Whether you need a single SLR or an ongoing evidence surveillance programme, our team is ready to collaborate.
